Home › NDC Lookup › Ingredients › Poliovirus Type 1 Antigen (Formaldehyde... › 49281-0860-10
IPOL POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED), POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED), and POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED) 1 ANTIGEN (FORMALDEHYDE INACTIVATED) 40 [D'ag'U]/.5mL; 2 ANTIGEN (FORMALDEHYDE INACTIVATED) 8 [D'ag'U]/.5mL; 3 ANTIGEN (FORMALDEHYDE INACTIVATED) 32 [D'ag'U]/.5mL Injection, Suspension — NDC 49281-0860-10 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

IPOL POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED), POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED), and POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED) 1 ANTIGEN (FORMALDEHYDE INACTIVATED) 40 [D'ag'U]/.5mL; 2 ANTIGEN (FORMALDEHYDE INACTIVATED) 8 [D'ag'U]/.5mL; 3 ANTIGEN (FORMALDEHYDE INACTIVATED) 32 [D'ag'U]/.5mL Injection, Suspension — NDC 49281-860-10 (Billing 49281-0860-10)

by Sanofi Vaccines US Inc. · 1 VIAL, MULTI-DOSE in 1 PACKAGE / 5 mL in 1 VIAL, MULTI-DOSE

This is a package of IPOL POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED), POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED), and POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED) 1 ANTIGEN (FORMALDEHYDE INACTIVATED) 40 [D'ag'U]/.5mL; 2 ANTIGEN (FORMALDEHYDE INACTIVATED) 8 [D'ag'U]/.5mL; 3 ANTIGEN (FORMALDEHYDE INACTIVATED) 32 [D'ag'U]/.5mL Injection, Suspension from Sanofi Vaccines US Inc., marketed since Dec 1990 and currently FDA-listed. It is this product's only package size.

NDC 49281-0860-10
🏷️ FDA NDC (as labeled) 49281-860-10 billing pads the product segment with a zero
Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 49281-860-10 alone.

Record
FDA NDC Directory package listing · Vaccine
Code segments
49281 labeler · 860 product · 10 package
Package marketed since
Dec 21, 1990
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC-A, from the NDC)
3 4928186010 2
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 49281-860-10
Product NDC 49281-860
11-digit billing NDC 49281086010
NCPDP billing unit ML — per mL (volume)
Application # BLA103930
SPL Set ID 34a647f5-8728-451b-b918-94c8acd15974
Established class (EPC) Inactivated Poliovirus Vaccine; Poliovirus Vacci
Physiologic effect Actively Acquired Immunity
Chemical class Poliovirus Vaccines
DEA schedule Non-controlled
Marketing category BLA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1990-12-21
Route INTRAMUSCULAR
Dosage form INJECTION, SUSPENSION
Substance POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED); POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED); POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED)
Biologic (Purple Book) 351(a)

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 17100050001800
GPI class Ipol
GCN Seq No 009648
GCN 43569
HICL code 004196
Ingredient (HICL) Poliomyelitis Vaccine, Killed
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W7
Therapeutic class — intermediate (HIC2) Biologicals
HIC3 code W7H
Therapeutic class — specific (HIC3) Enteric Virus Vaccines
AHFS code 80:12.00.00
AHFS class Vaccines
FDB label name IPOL VIAL
FDB brand name Ipol
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 009648
  • GCN: 43569
  • GPI-14 (Medi-Span): 17100050001800
  • HICL (First Databank): 004196
  • AHFS class code: 80:12.00.00
Why two NDCs? The FDA registers this code as 49281-860-10 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 49281-0860-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name IPOL VIAL Ingredient Poliomyelitis Vaccine, Killed
📖 What it is MedlinePlus · NLM

Why get vaccinated? Polio vaccine may prevent poliomyelitis that may occur with infection due to poliovirus. Infection with poliovirus can cause the following: illness with sore throat and fever that may progress to a brain infection and cause paralysis. Polio vaccine does not contain live virus. The vaccine works by triggering the body to make antibodies against the virus to provide a defense against potential infection.

Read the full MedlinePlus article ↗

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $90.41 $452.06 / 5 ml
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
49281-0860-10 You're viewing this Main listing 1 VIAL, MULTI-DOSE in 1 PACKAGE / 5 mL in 1 VIAL, MULTI-DOSE 1990-12-21 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Ipol 1 ANTIGEN (FORMALDEHYDE INACTIVATED) 40 [D'ag'U]/.5mL; 2 ANTIGEN (FORMALDEHYDE INACTIVATED) 8 [D'ag'U]/.5mL; 3 ANTIGEN (FORMALDEHYDE INACTIVATED) 32 [D'ag'U]/.5mL 50090-1693-09 A-S 1 vial — — FDA listed —
Ipol 1 ANTIGEN (FORMALDEHYDE INACTIVATED) 40 [D'ag'U]/.5mL; 2 ANTIGEN (FORMALDEHYDE INACTIVATED) 8 [D'ag'U]/.5mL; 3 ANTIGEN (FORMALDEHYDE INACTIVATED) 32 [D'ag'U]/.5mLthis 49281-0860-10 Sanofi 1 vial — — FDA listed —
About this product: this is a biologic. Biologics don't have small-molecule generics — competition comes from FDA-licensed biosimilars (shown above), not generics.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & biosimilar status

🏛️
2000
First FDA approval
Feb 2000
📍
2026
Currently FDA-listed
26 years listed
🧬
·
Biosimilars
see Purple Book
🧬Biologic — competition comes from biosimilars

Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.

Where does this data come from?
Patents and exclusivity from the FDA Purple Book (biologics), refreshed from public FDA data. Biosimilar launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • 20 ug / 0.5 mL UNII 1HG84L3525
    Formaldehyde is a preservative chemical that prevents bacterial and fungal growth in medicines. It keeps the product safe and stable during storage by stopping contamination.
  • 5 ng / 0.5 mL UNII I16QD7X297
    Neomycin is an antibiotic substance. In topical medicines, it serves as an active antimicrobial agent rather than an inactive excipient, helping prevent bacterial infection in wounds or skin conditions.
  • 3 uL / 0.5 mL UNII HIE492ZZ3T
    Phenoxyethanol is a synthetic preservative and antimicrobial agent used to prevent bacterial and fungal growth in medicines and cosmetic products, extending shelf life and maintaining product safety.
  • 25 ng / 0.5 mL UNII J2VZ07J96K
    Polymyxin B is an antibiotic derived from bacteria. In medicines, it serves as an active antimicrobial ingredient rather than an inactive excipient, used to fight bacterial infections in topical or injectable formulations.
  • 200 ng / 0.5 mL UNII Y45QSO73OB
    Streptomycin is an antibiotic derived from soil bacteria. In medicines, it serves as an active antimicrobial agent rather than an inactive excipient, used to treat bacterial infections.

5 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerSanofi Vaccines US Inc.
FDA applicationBLA103930 (BLA)
Labeler code49281
First marketedDec 1990
Product typeVaccine
Portfolio27 products on file

More NDCs from Sanofi Vaccines US Inc. labeler code 49281

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Ipol — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Ipol. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$626.7K
Claims incl. refills
9.5K
Beneficiaries
9.4K
Spend / beneficiary
$66.95
Spend / claim
$66.19
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Sanofi Vaccines US Inc.. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Sanofi Vaccines US Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 49281-0790-20 · Sanofi 49281-0912-05 · Sanofi →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.